*EARLY,† DURABLE‡ and DEEPER# responses with a favourable tolerability profile vs bosutinib, a 2nd-generation TKI^2,4
 

†MMR difference as early as Week 12.⁴ ‡Increased MMR benefit at week 24 maintained at week 96.^2,4 #Increased MR4 and MR4.5 at Week 24 and Week 96.^2,4.

How SCEMBLIX (asciminib) works

The first and only approved BCR-ABL1 inhibitor specifically targeting the ABL1 myristoyl pocket (STAMP)^2,3,5

SCEMBLIX targets a different site on the BCR-ABL1 compared to TKIs - the myrlstoyl pocket^2,3,5

In people who do not have CML, the myristoyl pocket is occupied by the N-terminal portion of ABL1, maintaining the protein in an inactive conformation.^6,7

In patients with CML, the myristoyl pocket on BCR-ABL1 is vacant, keeping the kinase in an active conformation.^6,7

SCEMBLIX is a first-in-class STAMP inhibitor. Binding specifically to the myristoyl pocket, it potently inactivates BCR-ABL1 via allosteric inhibition.²

AE, adverse event; CML, chronic myeloid leukaemia; MOA, mechanism of action; MMR, major molecular remission; Ph+ CML-CP, Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase; STAMP, Specifically Targeting the ABL1 Myristoyl Pocket; TKI, tyrosine kinase inhibitor; URTI, upper respiratory tract infection.

*Data from a retrospective, non-interventional study conducted at 21 UK NHS secondary and tertiary care centres on 257 CML patients.²

SCEMBLIX is indicated for the treatment of patients 18 years of age and above with:

• Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).
• Previously treated Ph+ CML in CP.
• Ph+ CML in CP with the T315I mutation